Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: A collaborative retrospective multicenter assessment

European Journal of Haematology

Volumn 96, Issue 2, 2016, Pages 136-143

  Gatt, Moshe E ^a   Hardan, Izhar ^b   Chubar, Evgeni ^c   Suriu, Celia ^d   Tadmor, Tamar ^e   Shevetz, Olga ^f   Patachenco, Paulina ^g   Dally, Najib ^h   Yeganeh, Shay ⁱ   Ballan Haj, Mouna ^j   Cohen, Yael ^k   Trestman, Svetlana ^k   Muchtar, Eli ^l   Magen, Hila ^l   Jakubinsky, Julia ^m   Avivi, Irit ^m  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c HAEMEK MEDICAL CENTER   (Israel)

^d WESTERN GALILEE HOSPITAL   (Israel)

^e BNAI ZION MEDICAL CENTER   (Israel)

^f KAPLAN MEDICAL CENTER   (Israel)

^g WOLFSON MEDICAL CENTER   (Israel)

^h Rebecca Sieff Government Hospital   (Israel)

ⁱ Poriya Hospital   (Israel)

^j CARMEL MEDICAL CENTER   (Israel)

^k TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^l RABIN MEDICAL CENTER   (Israel)

^m Rambam Health Care Campus ^*  (Israel)

more..

Author keywords

AL amyloidosis; Bortezomib; Chemotherapy; Novel agents

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; PARAPROTEIN; AMYLOID PROTEIN; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; ELECTROPHORESIS; FEMALE; HEART DISEASE; HUMAN; ISRAEL; LIGHT CHAIN; LIGHT CHAIN AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; HEART; HEART FAILURE; KIDNEY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; AMYLOIDOGENIC PROTEINS; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FEMALE; HEART; HEART FAILURE; HUMANS; KIDNEY; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84955191567     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12558     Document Type: Article

References (30)

1. Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998;82:1501-5.
2. Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica 2013;98:1492-5.
3. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2012;29:1924-33.
4. Gatt ME, Palladini G. Light chain amyloidosis 2012: a new era. Br J Haematol 2013;160:582-98.
5. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013;121:5124-30.
6. Gertz MA. I don't know how to treat amyloidosis. Blood 2010;116:507-8.
7. Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420-7.
8. Gertz MA. Allaying and alleviating amyloid agony and anxiety. Blood 2013;121:3301-2.
9. Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010;17(S1):48-49.
10. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia 2012;26:2317-25.
11. Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, Rajkumar SV, Gertz MA, Kumar SK. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc 2010;85:232-8.
12. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60.
13. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-9.
14. Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, Lavatelli F, Nuvolone M, Obici L, Perlini S, Merlini G. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia 2014;28:2311-6.
15. Venner CP, Gillmore JD, Sachchithanantham S, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia 2014;28:2304-10.
16. Kastritis E, Wechalekar A, Dimopoulos M, Merlini G, Hawkins P, Perfetti V, Gillmore J, Palladini G. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28:1031-7.
17. Lamm W, Willenbacher W, Lang A, Zojer N, Muldur E, Ludwig H, Schauer-Stalzer B, Zielinski CC, Drach J. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2011;90:201-6.
18. Wechalekar A, Lachmann H, Offer M, Hawkins P, Gillmore J. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93:295-8.
19. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391-4.
20. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119:4387-90.
21. Palladini G, Milani P, Foli A, Russo P, Lavatelli F, Obici L, et al. Treatment of AL amyloidosis with bortezomib combined with alkylating agents: results from a prospective series of unselected patients. ASH Annu Meet Abstr 2011;118:3977.
22. Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011;29:1916-23.
23. Merlini G, Stone M. Dangerous small B-cell clones. Blood 2006;108:2520-30.
24. Oliva L, Pengo N, Palladini G, Cascio P, Pasqualetto E, Merlini G, Sitia R, Cenci S. Proteasome activity and stress in light chain amyloidosis. Amyloid 2010;17(S1):99.
25. Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 2014;99:1479-85.
26. Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013;31:4319-24.
27. Merlini G. CyBorD: stellar response rates in AL amyloidosis. Blood 2012;119:4343-5.
28. Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M, Caccialanza R, Perlini S, Merlini G. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 2014;99:743-50.
29. Dispenzieri A. Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis. Leukemia 2014;28:2273-5.
30. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C, Antonio S, Mario P. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 2007;138:396-7.